不眠症治療薬市場：タイプ別、流通チャネル別-2025-2030年の世界予測

不眠症治療薬市場の2023年の市場規模は29億2,000万米ドルで、2024年には30億7,000万米ドルに達すると予測され、CAGR 5.67％で成長し、2030年には43億米ドルに達すると予測されています。

不眠症治療薬市場には、不眠症患者の睡眠の質と持続時間の改善を目的とした医薬品が含まれます。入眠障害や睡眠維持障害を特徴とする不眠症には、ベンゾジアゼピン系、非ベンゾジアゼピン系催眠薬、メラトニン受容体作動薬、オレキシン受容体拮抗薬などの効果的な医薬品が必要です。ストレス、ライフスタイルの変化、高齢化によって不眠症の有病率が高まっていることが、市場の必要性を強調しています。不眠症治療薬は、規則正しい睡眠パターンを取り戻すことで患者のQOL（生活の質）を向上させることを目的とし、病院、診療所、在宅介護の現場など、さまざまなエンドユーザーに応用されています。主な成長要因としては、メンタルヘルスに対する意識の高まりと、高度な睡眠障害治療の必要性が挙げられます。さらに、ヘルスケア支出の増加と薬剤製剤の技術的進歩が潜在的な機会をもたらしています。遠隔医療プラットフォームや医療提供者との連携を通じて治療へのアクセシビリティを拡大することで、市場へのリーチを高めることができます。しかし、長期使用に伴う副作用、厳しい規制当局の承認、認知行動療法のような副作用のない代替療法の出現といった課題が残っています。こうした限界に対処するためには、副作用の少ない薬剤の開発や、個別の治療レジメンに対応した個別化医療のアプローチに重点を置いた研究が必要です。迅速なドラッグデリバリーシステムや、睡眠を調節する中核経路をターゲットとする薬剤の革新は、市場の成長を促進する可能性があります。非中毒性、天然、持続可能な睡眠補助製品の研究開発への投資は、この競争市場において企業を差別化する可能性があります。さらに、ウェアラブル技術や睡眠モニタリング・アプリなどのデジタル・ヘルス・ツールを活用することで、患者のエンゲージメントと転帰の追跡を強化する機会がもたらされ、貴重な実世界データの洞察が得られます。現在の課題にもかかわらず、この市場は、特に薬理学的治療と患者のニーズに合わせた生活習慣への介入を統合した相乗的治療の開発において、大きな成長が期待されています。

市場力学：急速に進化する不眠症治療薬市場の主要市場インサイトを公開

不眠症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で増加する不眠症の有病率
  • 不眠症に利用可能な様々な治療オプションに関する意識の高まり
• 市場抑制要因
  • 不眠症治療薬に関連する副作用
• 市場機会
  • 新規不眠症治療薬を開発するための継続的な研究開発
  • 不眠症センターや睡眠診断センターの増加
• 市場の課題
  • 不眠症の深刻さに対する誤解と患者の治療不遵守

ポーターの5つの力：不眠症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：不眠症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、不眠症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析不眠症治療薬市場における競合情勢の把握

不眠症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス不眠症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、不眠症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨不眠症治療薬市場における成功への道筋を描く

不眠症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で不眠症の罹患率が増加
    • 不眠症のさまざまな治療法に対する認識の高まり
  • 抑制要因
    • 不眠症治療薬に関連する副作用
  • 機会
    • 新規研究開発開発不眠症治療薬
    • 不眠症センターおよび睡眠診断センターの増加
  • 課題
    • 不眠症の深刻さに関する誤解と患者の治療不遵守
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 不眠症治療薬市場：タイプ別

• 抗パーキンソン病薬
• 抗けいれん薬
• 抗うつ薬
• 抗ナルコレプシー薬
• ベンゾジアゼピン
• 非ベンゾジアゼピン
• オレキシン拮抗薬
• ラメルテオン

第7章 不眠症治療薬市場流通チャネル別

• オンライン薬局
• 小売薬局

第8章 南北アメリカの不眠症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の不眠症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの不眠症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Alembic Pharmaceuticals Limited
• Astellas Pharma Inc.
• Aurobindo Pharma Limited
• Biogen SA
• Cadila Healthcare Ltd.
• Dr.Reddy's Laboratories Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• Flynn Pharma Limited
• Glenmark Pharmaceuticals Ltd.
• Idorsia Pharmaceuticals Ltd.
• LA Herbal（India）
• Mallinckrodt Pharmaceuticals
• Merck & Co., Inc.
• Minerva Neurosciences, Inc.
• Neuracle Lifesciences Private Limited
• Neurim Pharmaceuticals LTD.
• Orexo AB
• Pfizer Inc.
• Purdue Pharma L.P.
• Sanofi Group
• Sun Pharmaceutical Industries Limited
• Takeda Pharmaceutical Company Limited
• Vanda Pharmaceuticals Inc.
• Wockhardt Limited

LIST OF FIGURES

• FIGURE 1. INSOMNIA DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. INSOMNIA DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. INSOMNIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. INSOMNIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INSOMNIA DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INSOMNIA DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTI-PARKINSONIAN DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTINARCOLEPTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NONBENZODIAZEPINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RAMELTEON, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 26. CANADA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. CANADA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 35. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. AUSTRALIA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. AUSTRALIA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 38. CHINA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CHINA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 40. INDIA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. INDIA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 42. INDONESIA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. INDONESIA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 44. JAPAN INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. JAPAN INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 46. MALAYSIA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. MALAYSIA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 48. PHILIPPINES INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. PHILIPPINES INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 50. SINGAPORE INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. SINGAPORE INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 52. SOUTH KOREA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. SOUTH KOREA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 54. TAIWAN INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. TAIWAN INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 56. THAILAND INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. THAILAND INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 58. VIETNAM INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. VIETNAM INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 62. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. DENMARK INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. DENMARK INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 65. EGYPT INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. EGYPT INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 67. FINLAND INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. FINLAND INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 69. FRANCE INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. FRANCE INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 71. GERMANY INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. GERMANY INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 73. ISRAEL INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. ISRAEL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 75. ITALY INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. ITALY INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 77. NETHERLANDS INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. NETHERLANDS INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 79. NIGERIA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. NIGERIA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 81. NORWAY INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. NORWAY INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 83. POLAND INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. POLAND INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 85. QATAR INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. QATAR INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 87. RUSSIA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. RUSSIA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 89. SAUDI ARABIA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SAUDI ARABIA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH AFRICA INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH AFRICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 93. SPAIN INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SPAIN INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 95. SWEDEN INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. SWEDEN INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 97. SWITZERLAND INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. SWITZERLAND INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 99. TURKEY INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. TURKEY INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED ARAB EMIRATES INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. UNITED ARAB EMIRATES INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 103. UNITED KINGDOM INSOMNIA DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. UNITED KINGDOM INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 105. INSOMNIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 106. INSOMNIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Insomnia Drugs Market was valued at USD 2.92 billion in 2023, expected to reach USD 3.07 billion in 2024, and is projected to grow at a CAGR of 5.67%, to USD 4.30 billion by 2030.

The insomnia drugs market encompasses pharmaceutical products designed to improve sleep quality and duration in individuals experiencing insomnia. Insomnia, characterized by difficulty in falling or staying asleep, necessitates effective medications like benzodiazepines, non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists. The growing prevalence of insomnia, driven by stress, lifestyle changes, and an aging population, underscores the market's necessity. It finds application across various end-users, including hospitals, clinics, and homecare settings, aiming to improve patient quality of life by restoring regular sleep patterns. Key growth factors include the increasing awareness of mental health and the need for advanced sleep disorder treatments. Additionally, rising healthcare expenditure and technological advancements in drug formulation present potential opportunities. Expanding the accessibility of treatments through telemedicine platforms and collaborations with healthcare providers can enhance market reach. However, challenges persist in the form of side effects associated with long-term usage, stringent regulatory approvals, and the emergence of side-effect-free alternative therapies like cognitive behavioral therapy. Addressing these limitations involves research focused on developing drugs with reduced adverse effects and personalized medicine approaches for individualized treatment regimens. Innovations in rapid drug delivery systems and drugs targeting core sleep-regulating pathways could advance market growth. Investment in R&D for non-addictive, natural, and sustainable sleep aid products could differentiate companies within this competitive market. Moreover, utilizing digital health tools, such as wearable technology and sleep monitoring apps, offers opportunities to enhance patient engagement and outcome tracking, providing valuable real-world data insights. Despite current challenges, the market holds significant promise for growth, particularly in the development of synergistic therapies, integrating pharmacological treatments with lifestyle interventions tailored to patient needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Insomnia Drugs Market

The Insomnia Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of insomnia across the world
  • Rising awareness about various treatment options available for insomnia
• Market Restraints
  • Side effects associated with insomnia drugs
• Market Opportunities
  • Continuous research and development to develop novel insomnia drugs
  • Increase in number of insomnia centers and sleep diagnostic centers
• Market Challenges
  • Misconceptions about the seriousness of insomnia and patients' non-adherence to the treatment

Porter's Five Forces: A Strategic Tool for Navigating the Insomnia Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Insomnia Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Insomnia Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Insomnia Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Insomnia Drugs Market

A detailed market share analysis in the Insomnia Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Insomnia Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Insomnia Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Insomnia Drugs Market

A strategic analysis of the Insomnia Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Insomnia Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Aurobindo Pharma Limited, Biogen SA, Cadila Healthcare Ltd., Dr.Reddy's Laboratories Limited, Eisai Co., Ltd., Eli Lilly and Company, Flynn Pharma Limited, Glenmark Pharmaceuticals Ltd., Idorsia Pharmaceuticals Ltd., LA Herbal (India), Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Minerva Neurosciences, Inc., Neuracle Lifesciences Private Limited, Neurim Pharmaceuticals LTD., Orexo AB, Pfizer Inc., Purdue Pharma L.P., Sanofi Group, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Vanda Pharmaceuticals Inc., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Insomnia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Anti-Parkinsonian Drugs, Anticonvulsants, Antidepressants, Antinarcoleptics, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, and Ramelteon.
• Based on Distribution Channels, market is studied across Online Pharmacies and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of insomnia across the world
    • 5.1.1.2. Rising awareness about various treatment options available for insomnia
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with insomnia drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Continuous research and development to develop novel insomnia drugs
    • 5.1.3.2. Increase in number of insomnia centers and sleep diagnostic centers
  • 5.1.4. Challenges
    • 5.1.4.1. Misconceptions about the seriousness of insomnia and patients' non-adherence to the treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Insomnia Drugs Market, by Type

• 6.1. Introduction
• 6.2. Anti-Parkinsonian Drugs
• 6.3. Anticonvulsants
• 6.4. Antidepressants
• 6.5. Antinarcoleptics
• 6.6. Benzodiazepines
• 6.7. Nonbenzodiazepines
• 6.8. Orexin Antagonist
• 6.9. Ramelteon

7. Insomnia Drugs Market, by Distribution Channels

• 7.1. Introduction
• 7.2. Online Pharmacies
• 7.3. Retail Pharmacies

8. Americas Insomnia Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Insomnia Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Insomnia Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alembic Pharmaceuticals Limited
• 2. Astellas Pharma Inc.
• 3. Aurobindo Pharma Limited
• 4. Biogen SA
• 5. Cadila Healthcare Ltd.
• 6. Dr.Reddy's Laboratories Limited
• 7. Eisai Co., Ltd.
• 8. Eli Lilly and Company
• 9. Flynn Pharma Limited
• 10. Glenmark Pharmaceuticals Ltd.
• 11. Idorsia Pharmaceuticals Ltd.
• 12. LA Herbal (India)
• 13. Mallinckrodt Pharmaceuticals
• 14. Merck & Co., Inc.
• 15. Minerva Neurosciences, Inc.
• 16. Neuracle Lifesciences Private Limited
• 17. Neurim Pharmaceuticals LTD.
• 18. Orexo AB
• 19. Pfizer Inc.
• 20. Purdue Pharma L.P.
• 21. Sanofi Group
• 22. Sun Pharmaceutical Industries Limited
• 23. Takeda Pharmaceutical Company Limited
• 24. Vanda Pharmaceuticals Inc.
• 25. Wockhardt Limited